Breast cancer · curated MDI catalog

Molecular tests for breast cancer

Breast-cancer molecular testing includes prognostic assays, hereditary-risk testing, treatment profiling and monitoring. These uses are not interchangeable, and performance belongs to a defined population and assay version.

23 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

  • BRCAplus — Guideline-based germline hereditary breast cancer panel.
  • Breast Cancer Index — PCR-based breast tumor gene-expression LDT providing distant-recurrence risk and likelihood of benefit from extended endocrine therapy.
  • CancerNext — Guideline-based germline hereditary cancer panel.
  • CancerNext-Expanded — Germline hereditary-cancer panel; current vendor page reports 78 genes while recent official 77-gene materials require explicit version separation.
  • EndoPredict — Gene-expression prognostic test for recurrence risk in early-stage HR-positive/HER2-negative breast cancer.
  • EPISEEK — Blood-based multi-cancer early detection LDT analyzing abnormal DNA methylation signals associated with more than 60 cancer types.
  • FoundationOne MRD — Tissue-informed ctDNA MRD assay for stage II-III breast cancer using tumor WGS and multiplex dPCR.
  • Guardant Reveal — Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
  • Guardant360 Liquid CDx — Plasma cfDNA comprehensive genomic profiling and indication-specific companion diagnostic.
  • Invitae Common Hereditary Cancers Panel — NGS germline panel for common hereditary cancer predisposition.
  • Invitae Hereditary Breast and Gyn Cancers Panel — NGS germline panel for hereditary breast and gynecologic cancer predisposition.
  • Invitae Personalized Cancer Monitoring — Tumor-informed personalized ctDNA monitoring assay for solid tumors.
  • LucenceINSIGHT — Prescription blood-based multi-cancer early detection family using ctDNA and viral DNA with machine-learning tissue localization.
  • MammaPrint — 70-gene breast-cancer genomic risk classifier with multiple historical/current platform configurations that must remain version scoped.
  • MyRisk — Germline hereditary-cancer panel; current documented configuration contains 63 clinically recommended genes and must not inherit analytical metrics from historical 25-gene validation.
  • NeXT Personal Dx — Tumor-informed personalized ctDNA LDT using WGS-derived patient-specific signatures for MRD, recurrence and treatment-response monitoring.
  • Oncotype DX Breast Recurrence Score — 21-gene tumor RNA expression assay used in HR-positive, HER2-negative early breast cancer to estimate recurrence risk and inform potential chemotherapy benefit.
  • Precise MRD — Tumor-informed whole-genome sequencing MRD assay tracking up to 1,000 patient-specific variants for treatment and recurrence monitoring.
  • Prosigna — PAM50/ROR breast-cancer prognostic classifier; historical FDA-cleared nCounter IVD and current US NGS LDT are distinct configurations.
  • RaDaR ST — Personalized tumor-informed ctDNA MRD assay for solid tumors; current ST generation uses WES tumor profiling and tracks up to 48 patient-specific mutations.
  • SPOT-MAS 10 — Blood-based multi-cancer screening test using cfDNA methylation and fragmentomic signals with machine learning.
  • Tempus xF+ — 523-gene plasma liquid-biopsy comprehensive genomic profiling assay for therapy selection and molecular profiling in advanced cancer.
  • therascreen PIK3CA RGQ PCR Kit — FDA-approved real-time PCR PIK3CA companion diagnostic for breast cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance